BC Platforms, a leader in healthcare data technologies, has partnered with OmicsBank to integrate large-scale, AI-ready clinical and multi-omics datasets from India and the UAE into its global network. The collaboration adds over 12 million patient lives from India and 500,000 from the UAE, boosting total coverage to more than 187 million across 35+ countries. This move enhances access to diverse, longitudinal real-world data including EMRs, pathology slides, imaging, sequencing, and biospecimens for drug discovery, precision medicine, and advanced AI model training.
Glimpse:
Announced on February 5, 2026, the strategic partnership allows BC Platforms to incorporate OmicsBank’s extensive, research-ready datasets from emerging markets into its platforms (BC Unify, BC Mosaic, and BC Catalyst). These include millions of electronic medical records, pathology images, medical imaging, genomic sequencing, and linked biospecimens. The expansion supports faster insights for life sciences companies, enabling better understanding of disease diversity in underrepresented populations, targeted therapies, real-world evidence generation, and multimodal AI development. Plans are underway to further scale coverage across India and into markets like Saudi Arabia, Taiwan, the Philippines, and Malaysia.
BC Platforms, a Zurich-based global leader in healthcare data management, analytics, and technology, has announced a major strategic partnership with OmicsBank, a healthcare AI-ready data infrastructure company focused on emerging markets. The collaboration, revealed on February 5, 2026, integrates OmicsBank’s high-quality, longitudinal datasets from India and the United Arab Emirates (UAE) into BC Platforms’ worldwide data network, dramatically expanding access to diverse real-world clinical and multi-omics information.
OmicsBank provides millions of electronic medical records (EMRs), large collections of pathology slides and medical imaging, extensive sequencing data, and connected biospecimens. These resources are structured for research use, available as modular datasets or comprehensive longitudinal cohorts. Through the partnership, BC Platforms adds more than 12 million patient lives from India and approximately 500,000 from the UAE, bringing its global reach to over 187 million patient lives across more than 35 countries.
Once integrated into BC Platforms’ agentic AI data mastering platform (BC Unify), the data is harmonized and made accessible via BC Mosaic a federated, trusted research environment and BC Catalyst, which delivers actionable insights and predictive analytics. This infrastructure empowers life sciences companies, researchers, and clinicians to conduct activities ranging from early drug discovery and feasibility studies to clinical development, real-world evidence generation, post-market surveillance, and large-scale training of advanced multimodal AI models.
India’s vast population scale, genetic diversity, and increasing role in clinical research make its data especially valuable for precision medicine and targeted therapies. The partnership addresses underrepresentation of non-Western populations in global datasets, helping address unique disease patterns and regulatory needs. Future expansions will deepen coverage in India and extend to additional emerging markets, including Saudi Arabia, Taiwan, the Philippines, and Malaysia, as OmicsBank grows its hospital and diagnostic lab partnerships.
The collaboration underscores the growing importance of diverse, high-quality real-world data in accelerating innovation, reducing development timelines, and enabling personalized healthcare solutions worldwide.
“Infections, especially bloodstream infections, remain one of the toughest diagnostic challenges in medicine. Traditional cultures can take days and often miss the pathogen entirely. MetaSeq changes that equation giving clinicians a broad, rapid, and unbiased view of what’s happening in the patient’s body, so we can move from guesswork to targeted treatment much faster.”
By
HB Team
